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Inhaled Nitric Oxide in Primary Pulmonary Hypertension
A Safe and Effective Agent for Predicting Response to Nifedipine
MARK J. RICCIARDI, MD,* BRADLEY P. KNIGHT, MD,* FERNANDO J. MARTINEZ, MD,†
MELVYN RUBENFIRE, MD, FACC*
Ann Arbor, Michigan
Objectives. The purpose of this study was to assess the utility of
inhaled nitric oxide (NO), a selective pulmonary vasodilator, for
predicting the safety and acute hemodynamic response to high-
dose oral nifedipine in primary pulmonary hypertension (PPH).
Background. A significant decrease in pulmonary vascular
resistance with an oral nifedipine challenge is predictive of an
improved prognosis, and potential clinical efficacy in PPH. How-
ever, the required nifedipine trial carries significant first-dose
risk of hypotension. While inhaled NO has been recommended for
assessing pulmonary vasodilator reserve in PPH, it is not known
whether it predicts the response to nifedipine.
Methods. Seventeen patients with PPH undergoing a nifedipine
trial were assessed for hemodynamic response to inhaled NO at 80
parts per million for 5 minutes. The nifedipine trial consisted of
20 mg of nifedipine hourly for 8 hours unless limited by hypoten-
sion or intolerable side effects. Patients were classified as re-
sponders and nonresponders with positive response defined as
>220% reduction in mean pulmonary artery pressure (mPA) or
pulmonary vascular resistance (PVR) with the vasodilator admin-
istration.
Results. NO was safely administered to all participants. Seven
of 17 (41.2%) responded to NO, and 8 of the 17 to nifedipine
(47.1%). Nifedipine was safely administered in 14 of the 17. Three
suffered either mild or severe hypotension, including one death.
All NO responders also responded to nifedipine, and 9 of the 10
NO nonresponders were nifedipine nonresponders, representing a
sensitivity of 87.5%, specificity of 100%, and overall predictive
accuracy of 94%. All NO responders tolerated a full nifedipine
trial without hypotension. There was a highly significant correla-
tion between the effects of NO and nifedipine on PVR (r 5 0.67,
p 5 0.003).
Conclusions. The pulmonary vascular response to inhaled NO
accurately predicts the acute hemodynamic response to nifedipine
in PPH, and a positive response to NO is associated with a safe
nifedipine trial. In patients comparable with those evaluated, a
trial of nifedipine in NO nonresponders appears unwarranted and
potentially dangerous.
(J Am Coll Cardiol 1998;32:1068–73)
©1998 by the American College of Cardiology
Primary pulmonary hypertension (PPH) is a rapidly progres-
sive and fatal disease (1). While no cure has been identified,
anticoagulants (2,3), calcium channel blockers (3), and contin-
uous infusion epoprostenol (4) have proven useful. The addi-
tion of epoprostenol to conventional therapy in patients with
advanced symptoms improved 90-day survival, quality of life,
and exercise capacity in Class III and IV patients (5). Despite
the clear benefits of epoprostenol, there are patients for whom
the risk of implanted catheter-related infection and cost will be
excessive (e.g., those with less advanced symptoms and those
who may derive benefit from calcium channel blocker therapy).
Further, the availability of echo-Doppler for detecting pulmo-
nary hypertension and heightened awareness of PPH related to
dexfenfluramine (Redux) (6) make it likely more patients will
be diagnosed at earlier stages. Until more effective oral agents
become available, an important part of patient management
will be selecting those for whom conventional therapy with
calcium channel blockade is appropriate.
Because the long-term efficacy of nifedipine and diltiazem
correlates with the acute response, the decision to use these
agents has historically been based upon a hemodynamic trial.
However, the invasive trials are labor intensive, require an
intensive care unit (ICU) stay for 1–2 days, and have been
associated with profound hypotension and death (7).
Acute hemodynamic trials with intravenous adenosine (7–
12) and prostacyclin (13,14) have been used to evaluate
pulmonary vascular vasodilator reserve in PPH, and as
“screening vasodilators” for determining which patients may
benefit from chronic oral calcium channel blocker therapy.
Each is a nonselective vasodilator known to produce systemic
side effects (11,13,14).
Nitric oxide (NO) is an endogenous endothelial–derived
vasodilator mediated by vascular smooth muscle cell cGMP.
When administered as an inhaled gas in patients with both
primary and secondary forms of pulmonary hypertension,
short-term NO selectively reduces both the mean pulmonary
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artery pressure (mPA) and pulmonary vascular resistance
(PVR) with no side effects (15–18). While established as a
selective pulmonary artery vasodilator and recommended as a
suitable agent for pulmonary vasodilator testing, it is not
known whether inhaled NO predicts the response to nifedi-
pine.
We designed this study to evaluate the utility of inhaled NO
for predicting the safety and pulmonary vascular response to a
trial of high-dose oral nifedipine in PPH.
Methods
Seventeen patients with PPH (NIH criteria) scheduled to
undergo an acute challenge with high-dose nifedipine to assess
pulmonary vasodilator reserve also consented to a brief trial of
inhaled NO. The study was approved by the Institutional
Review Board of the University of Michigan. Patients with
evidence for pulmonary veno-occlusive disease or systemic
systolic pressure less than 90 mm Hg were excluded.
Hemodynamic assessment. Oral vasodilating drugs were
held for 24 h. No sedation was used prior to or during the
studies, and all trials were conducted in the fasting state. A
radial or femoral artery 4 or 5 French catheter was inserted for
pressure monitoring and blood gas analysis. A four-lumen
balloon flotation catheter (optional use of a stiffening wire)
was used for thermodilution cardiac output (CO), sampling of
mixed venous oxygen saturation, and right heart pressures. The
NO trial was conducted in the cardiac catheterization labora-
tory or coronary care unit (CCU), and the nifedipine trial the
following morning in the CCU.
Thermodilution CO was defined as the average of the first
two measurements if within 5%, or three within 10% agree-
ment. Arterial and mixed venous blood samples were obtained
at the time of thermodilution CO. The following pressures
were obtained at 100 mm Hg scale and 50 mm/s paper speed
and measured in mm Hg as the average during three respira-
tory cycles: mean right atrial (mRA); systolic and diastolic
pulmonary artery; mean pulmonary capillary wedge (PCW);
and systolic and diastolic systemic artery. Mean arterial (mBA
or mFA) and mPA pressures were calculated using the average
of one systolic and two diastolic divided by three. Systemic
vascular resistance (SVR) and PVR were calculated as
(mBA 2 mRA) 4 CO and (mPA 2 PCW) 4 CO, respectively,
and expressed in absolute or Wood units.
Nitric oxide trial. Baseline measures for the NO trial were
obtained on room air if the pO2 was .60 mm Hg and arterial
saturation .90%. Two patients required supplemental oxygen
(FIO2 24% and 28%) to maintain arterial saturation $92%. In
three patients with right to left shunting at the atrial level (one
atrial septal defect and two foramen ovale) the maximum
arterial saturation was ,92% on 28% FIO2. NO was admin-
istered for 7 minutes at 80 parts per million (PPM) with a tight
fitting mask, and data were collected in the last 2 minutes. The
dose of NO and generation of nitrogen dioxide were measured
using an NO delivery system (NOxBOX II; Bedfont Scientific)
and NO analyzer (Sensormedics SensorNOx; Sensormedics
BV).
Nifedipine trial. Patients were administered a constant
infusion of 5% dextrose and 0.5 NaCL at 50–75 cc/h starting 8
hours prior and throughout the nifedipine trial. The nifedipine
trial consisted of 20 mg of nifedipine given hourly for 8 hours
unless limited by systemic hypotension (systolic pressure re-
duction greater than 20% accompanied by symptoms attribut-
able to hypotension, or absolute value of less than 90 mm Hg)
or intolerable side effects (19). The reference baseline was
defined as the average over 4 hours preceding the first dose of
nifedipine. All hemodynamic data were obtained in the recum-
bent position.
Response to vasodilator. Complications were a priori de-
fined as major or minor. Major complications included hypo-
tension requiring treatment, cardiogenic shock, or death. Mi-
nor complications were defined as symptoms requiring
termination prior to completion of the dosing schedule.
Response to NO and nifedipine in comparison with base-
line measures were calculated as absolute change and percent
change, and expressed as responders or nonresponders. Al-
though not uniformly established in the literature (7,11,12,19),
responders were defined a priori as those with a decrease in
mean pulmonary artery pressure (mPA) or pulmonary vascular
resistance of $20% (12) without significant systemic hypoten-
sion. Those who developed severe systemic hypotension, for
whom significant hemodynamic assessment was not possible,
were assigned mPA and PVR reduction of 0% (i.e., fixed
pulmonary vascular response to vasodilation).
Statistical analysis. Sensitivity, specificity, predictive value,
and predictive accuracy were calculated using true positive and
true negative results defined as identifying nifedipine respond-
ers and nonresponders, respectively. Between group compari-
sons were made by the Student t test. Pearson correlation
coefficient was used to compare nifedipine and NO responses.
Linear regression modeling was used to test the predictability
of nifedipine response by NO and hemodynamic measures.
Results
Patient population. All 17 patients completed both trials.
The average age of participants was 47.5 6 14 years; 88% were
women. The majority of patients were obese (body mass index
[BMI] .27.5 kg/M2). The mean weight was 81.1 6 20 kg,
height 1.7 6 0.1 M, and BMI 29.6 6 5.3 kg/M2. Three patients
were NYHA functional Class II, 11 Class III, and three Class
IV. The study population probability for 1-year survival based
Abbreviations and Acronyms
CO 5 cardiac output
mPA 5 mean pulmonary artery pressure
mRA 5 mean right atrial pressure
NO 5 nitric oxide
PPH 5 primary pulmonary hypertension
PVR 5 pulmonary vascular resistance
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on the NIH registry formula, which incorporates RA pressure,
mPA pressure, and CO (20), was 67.5 6 16%. Baseline mRA
was 11.0 6 7 mm Hg, mPA 57.5 6 12 mm Hg, CO 4.7 6 2 L/m,
PVR 11.5 6 6 Wood units, mBA 92.8 6 14 mm Hg, systemic
O2 saturation 92 6 7%, and mixed venous saturation (MVO2)
64 6 10% (Table 1). Arterial saturation was less than 85% in
two patients; one with a low-affinity hemoglobin (hemoglobin
Washtenaw, patient #8), and one an atrial septal defect with
bi-directional shunting (patient #17).
NO response. NO was administered without side effects in
all 17 patients. Three patients had mild transient arterial
desaturation (to 88%). NO administration resulted in a mean
reduction in mPA pressure from 57.5 6 12.4 to 54.0 6
12.8 mm Hg (6.3 6 9.3%, p 5 NS), and mean reduction in
PVR from 11.2 6 5.4 to 10.2 6 5.8 Wood units (11.4 6 19.1%,
p 5 NS). Additionally, there was no significant change in heart
rate, mean systemic blood pressure, arterial saturation, mixed
venous saturation, pulmonary capillary wedge pressure, or
cardiac output. NO response is summarized in Table 2.
Seven of the 17 patients (41.2%) were NO responsive. The
mean percent reduction in mPA in NO responders and non-
responders was 12.3 6 8.9% and 2.2 6 7%, respectively (p 5
0.03). The mean percent reduction in PVR was 29.3 6 11.0%
and 21.2 6 12.1% for NO responders and nonresponders,
respectively (p 5 0.00007).
Nifedipine response. Nifedipine was administered safely in
14 of the 17 patients. Two patients experienced first-dose
severe hypotension and shock (one death, one successfully
treated), and one had mild hypotension. Those with hemody-
namic instability could not undergo complete hemodynamic
assessment and were assigned mPA and PVR reduction of 0%
(i.e., fixed pulmonary hypertension). The mean nifedipine dose
was 129.4 6 52 mg. Nifedipine administration resulted in a
reduction in mPA from 59.1 6 11.1 to 53.4 6 11.0 mm Hg
(8.0 6 10%, p 5 NS), and reduction in PVR from 12.6 6 6.1
to 9.3 6 5.1 Wood units (19.7 6 13%, p 5 NS). The mean
systemic blood pressure, in those without severe hypotension,
fell from 92.5 6 15.3 to 74.8 6 12.9 mm Hg (p 5 0.001). There
was no significant change in heart rate, arterial saturation,
mixed venous saturation, pulmonary capillary wedge pressure,
or CO. Nifedipine response is summarized in Table 2.
Of the 17 patients, 8 (47.1%) were nifedipine responders.
The mean percent reduction in mPA in responders and
nonresponders was 11.3 6 11% and 2.8 6 7.8%, respectively
(p 5 0.09). The mean percent reduction in PVR was 28.6 6
10% and 10.2 6 8% for responders and nonresponder, respec-
tively (p 5 0.02).
Comparison of NO and nifedipine response. All seven of
the NO responders responded to nifedipine and nine of the 10
NO nonresponders were nifedipine nonresponders. NO pre-
dicted the response to nifedipine with a sensitivity of 87.5%,
specificity of 100%, positive predictive value of 100%, and
negative predictive value of 94%. The overall predictive accu-
racy of NO was 94%. All NO responders tolerated nifedipine
without hypotension.
The percent change in PVR with the two vasodilators was
normally distributed. There was a significant correlation be-
tween the effects of NO and nifedipine on PVR (Pearson’s r 5
0.67, p 5 0.003, (Fig. 1). Linear regression analysis showed NO
to predict nifedipine response independent of mRA, mPA
pressure, and CO. No hemodynamic measure, alone or in
combination, was predictive of response to nifedipine.
Discussion
The mean survival in PPH from symptom onset is approx-
imately 3 years (21). Patients generally present with progres-
sive exertional dyspnea, fatigue, and chest pressure and ulti-
mately develop severe hypoxemia and death due to
hypotension and low output or a fatal ventricular arrhythmia.
The outcome has, to varying degrees, been favorably impacted
by four treatment modalities; anticoagulation (2,3), oral cal-
cium channel blocking drugs (3), continuous infusion epopro-
stenol (4), and lung transplantation (22).
Continuous infusion of intravenous epoprostenol appears
to change the natural history of PPH, and has been approved
for use in the United States for patients with moderate to
severe symptoms (NYHA Class III and IV). When added to
conventional treatment (66% of whom were an oral vasodila-
tor therapy), epoprostenol has been shown to reduce mortality
and symptoms, and delay the need for lung transplantation (5).
The expense and necessity for an indwelling catheter and
infusion pump make epoprostenol less than an ideal agent,
particularly in those without severe limitation. Subgroups of
patients in whom oral calcium channel blocker therapy may be
effective include those with mild to moderate symptoms and
moderately increased pulmonary vascular resistance, and pos-
Table 1. Study Population
Demographic Data Hemodynamic Data
No. of patients 17 RA 11.4 6 7.0 mm Hg
Age 45 6 14 years sPA 92 6 19 mm Hg
Female 88.2% dPA 40 6 10 mm Hg
BSA 1.9 6 0.3 kg/m2 mPA 57.5 6 12.4 mm Hg
NYHA Class 3 6 0.6 PCWP 12.4 6 3.0 mm Hg
Est. 1-year survival 67.5 6 16.4% sBA 130 6 21 mm Hg
dBA 75 6 13 mm Hg
mBA 88.5 6 14.1 mm Hg
CO 4.6 6 1.6 L/min
art O2 sat 91.9 6 7%
MVO2 63.9 6 10%
PVR 11.2 6 5.4 Wood Units
Baseline patient demographic and hemodynamic data. s 5 systolic; d 5
diastolic; m 5 mean; RA 5 right atrium; BA 5 brachial artery; PA 5 pulmonary
artery; CO 5 cardiac output; PCWP 5 pulmonary artery occlusive pressure;
MVO2 5 mixed venous oxygen; BSA 5 weight (kg)/height (m
2); Est. 1-year
survival as calculate using NIH registry formula (20); RA 5 mean right atrial
pressure; PA(s/d) 5 pulmonary artery pressure systolic over diastolic; mPA 5
mean pulmonary artery pressure; PCWP 5 mean pulmonary capillary wedge
pressure; BP 5 systemic blood pressure; mBA 5 mean systemic pressure; CO 5
cardiac output by thermodilution, art O2 sat 5 arterial oxygen saturation by
blood gas analysis; MVO2 5 mixed venous oxygen saturation by blood gas
analysis; PVR 5 pulmonary vascular resistance ([mPA-wedge pressure]/CO).
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sibly those with Class III symptoms with good pulmonary
vasodilator reserve (a subset of patients not separately identi-
fied in the epoprostenol trials) (1,3,5).
Nifedipine trial safety. Only 25% of PPH patients have a
favorable hemodynamic response and symptomatic benefit
from calcium channel blocking agents, and there is a significant
risk in their administration (3,19). The nonselective vasodila-
tion and negative inotropy associated with calcium blockade
may result in fatal or near fatal systemic hypotension. While
several hemodynamic parameters (markedly elevated mRA,
mPA, and depressed CO) may identify a group at risk for
adverse effects, the evaluation of pulmonary vascular reserve
prior to nifedipine challenge has become standard of care (7).
The use of short-acting intravenous vasodilators to select patients
for a trial with calcium channel blockers has been recommended,
but no agents have been approved for such use (1).
Predicting nifedipine response with adenosine. The response
to intravenous adenosine has been shown to correlate with that
of nifedipine. In the largest reported trial of adenosine use in
PPH (15 patients), Schrader et al. (11) found adenosine
response to reasonably predict response to nifedipine. How-
ever, two of 12 adenosine responders had hypotension with
nifedipine administration, suggesting that demonstration of
pulmonary vasodilator reserve with adenosine does not predict
a safe nifedipine trial. A second study reported that a subgroup
of adenosine responders developed systemic hypotension with
nifedipine (23). This may be a function of differing dose
response, broader pulmonary vascular effects with adenosine
than nifedipine, or possibly greater negative inotropic effects of
nifedipine on right and left ventricular function.
Predicting nifedipine response with prostacyclin. The acute
hemodynamic response to prostacyclin also correlates reason-
ably well with the initial hemodynamic response to nifedipine,
and has been used to select patients for nifedipine trials (14).
Additionally, prostacyclin responders have a better long-term
response to nifedipine than nonresponders. The response to
intravenous PGI2, available as epoprostenol, has been recom-
mended as an equivalent alternative to adenosine for selecting
patients for an oral calcium channel blocker trial (1). However,
the sensitivity and specificity of predicting nifedipine response
with prostacyclin testing is not known.
Nitric oxide. Inhaled NO selectively dilates the pulmonary
vasculature, has minimal systemic side effects, and with the aid
of a respiratory therapist is easily administered. Continuous
NO has been safely administered for days in children with
pulmonary hypertension (24,25), adults with respiratory dis-
tress syndromes (26), and as bridge to lung transplantation
(27). Because of a very short half life measurable in seconds, it
is particularly useful as a testing agent. Prolonged use at high
doses (especially in ventilated patients on high flow oxygen)
may result in the accumulation of toxic byproducts; namely
nitric dioxide (NO2) (28–30). Accurate simple tools for mea-
suring the concentration of inhaled NO and NO2 are readily
available. Given these favorable properties, NO has been
recommended as a suitable agent for acute pulmonary vasodi-
lator testing. Unlike adenosine and epoprostenol though, NO
has not previously been shown to predict nifedipine response.
This study was designed to test whether NO could predict
the safety and short-term efficacy of nifedipine in PPH. The
long-term outcome in the NO and nifedipine responders was
not evaluated in this study, as all nonresponders were treated
with continuous infusion epoprostenol (thus confounding pa-
tient outcomes). Pulmonary vasodilator response to 5 minutes
of 80 PPM of inhaled NO was compared with the hourly
administration of 20 mg of nifedipine to a maximum of eight
doses or intolerance. NO was administered without untoward
effects in all patients, and all NO responders underwent a safe
nifedipine trial. NO accurately predicted nifedipine response
in 94%. Only one patient was misclassified with NO.
Conclusions. The pulmonary vascular response to inhaled
NO accurately predicts the acute hemodynamic response to
nifedipine in PPH, and should be considered as a safe alter-
native to adenosine and prostacyclin for vasodilator testing. In
patients comparable with those evaluated herein, a trial of
nifedipine in NO nonresponders with severely elevated PVR
appears unwarranted and potentially dangerous. When compared
with published reports on adenosine in PPH, NO responders
would appear to have a higher likelihood of a safe nifedipine trial
with comparable or better predictive value of nifedipine response.
Ongoing studies with larger numbers of patients will address
whether, as this study suggests, a favorable acute response to NO
ensures a safe trial with nifedipine. Whether the initial response
to inhaled NO is predictive of the long-term efficacy of calcium
channel blockade awaits further study.
We gratefully acknowledge Sherrie Howie, RN, and the University of Michigan
Internal Medicine housestaff who assisted in patient care, and Nancy Field for
manuscript preparation.
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